ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1715800
This article is part of the Research TopicTechnologies for Diabetes, volume IIIView all 9 articles
Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study
Provisionally accepted
- 1Maribor University Medical Centre, Maribor, Slovenia
- 2Univerzitetni Klinicni Center Maribor, Maribor, Slovenia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Basal insulin with glucagon-like peptide-1 receptor agonist could be preferred over premixed insulin for intensification in type 2 diabetes due to better glycemic control, lower hypoglycemia risk, and favorable effects on body weight. Comparative data on premixed insulin and the combination of degludec and liraglutide (iDegLira) are limited. Methods: We conducted a 24-week single-arm prospective study to evaluate the impact of iDegLira compared to premixed insulin on the regulation of diabetes and glucovariability using continuous glucose monitoring (CGM), HbA1c, and anthropometric measurements. A total of 37 participants with type 2 diabetes (20 male and 17 female, aged 70.2 ±10.0 years with BMI 31.0 (28.0-34.0) kg/m2 and duration of diabetes for 15.2 ± 7.7 years) were switched from premixed insulin treatment to iDegLira. The primary outcome was the change in HbA1c. Secondary outcomes included change in time in range (TIR) from baseline to 6 months, change in time below range (TBR), change in nocturnal hypoglycemia, glucovariability, insulin dose and body weight. Results: We observed improved glycemic control on iDegLira with improvement of average fasting glucose (6.92 ±1.64 vs. 8.25 ±2.2 mmol/l; p<0.031), HbA1c (7.10±0.7% vs. 7.39±0.7% p=0.045) and TIR (71.2±17.2% vs. 64.3 ± 18.0; p=0.027). These results were accompanied by a nearly halved total daily insulin dose (-21 units/day, p<0.001) and a modest reduction of body weight. Discussion: iDegLira improved glycemic control, resulting in a lower HbA1c and higher TIR, alongside beneficial effects on body weight and total daily insulin doses. While numerical reductions in hypoglycemia did not reach statistical significance, treatment was not associated with an increased risk of hypoglycemia. iDegLira can be an efficient and safe treatment option, providing simplified treatment with improved glycemic control.
Keywords: Diabetes Mellitus, Premixed insulin, GLP-1 analogue, IDegLira, continuous glucosemonitoring (CGM), CGM targets
Received: 29 Sep 2025; Accepted: 23 Oct 2025.
Copyright: © 2025 Kravos Tramšek, Koceva and Krajnc. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Nika Aleksandra Kravos Tramšek, nikakravos@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.